CagriSema vs tirzepatide for obesity

A network meta-analysis published in Endocrinology, Diabetes & Metabolism in July 2026 pooled data from 25 randomised trials to compare the weight-loss efficacy and safety of CagriSema, semaglutide, cagrilintide, and tirzepatide across 12 different dosing regimens^[1].

The headline finding: tirzepatide 15 mg ranked first for mean percent weight reduction, followed closely by CagriSema. But network meta-analyses work by connecting trials through shared comparators (usually placebo), so these rankings reflect indirect comparisons, not head-to-head data. That distinction matters here, because a direct head-to-head trial between CagriSema and tirzepatide has already reported, and it told a slightly different story.

What the meta-analysis reported

The authors, led by Sultan Hamarsheh, included 25 randomised controlled trials spanning 12 interventions. Tirzepatide 15 mg produced the largest mean percent weight reduction at 17.97%, followed by CagriSema at 17.84% and semaglutide 2.4 mg at 14.66%, all compared with placebo^[1].

For the threshold of achieving at least 20% body-weight loss, CagriSema ranked first (relative risk 27.82 versus placebo), with tirzepatide 15 mg close behind (relative risk 23.70)^[1]. Lower doses of tirzepatide (5 mg and 10 mg) and semaglutide (1.0 mg and 2.4 mg) filled in the middle of the ranking. Cagrilintide alone appeared lower in the hierarchy.

On safety, gastrointestinal adverse events (nausea, vomiting, diarrhoea) were elevated across all active treatments, with relative risks ranging from 1.33 to 1.91 compared with placebo. Serious adverse events, though, remained comparable to placebo across all regimens^[1].

How network meta-analyses work, and where they fall short

A network meta-analysis connects trials that share a common arm (typically placebo) and estimates how treatments compare even when they were never tested directly against each other. The method is useful for mapping a competitive field, but the estimates carry wider uncertainty than direct head-to-head trials. Differences in trial populations, treatment duration, titration schedules, and endpoint definitions all introduce noise that the statistical model tries to account for but cannot fully eliminate.

In this case, the 25 trials spanned different durations (some 68 weeks, others shorter), different baseline BMI ranges, and different proportions of participants with type 2 diabetes. The authors acknowledge these limitations in the paper.

What the direct head-to-head trial showed

The REDEFINE 4 trial, reported in February 2026, was an 84-week, open-label, head-to-head study of CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) versus tirzepatide 15 mg in 809 adults with obesity. CagriSema produced 23.0% mean weight loss; tirzepatide 15 mg produced 25.5%. The trial's prespecified primary objective of demonstrating non-inferiority for CagriSema was not met^[2].

That result is worth reading alongside the network meta-analysis. The NMA ranked CagriSema and tirzepatide 15 mg as nearly equivalent (17.84% vs 17.97%). The direct trial, with a longer treatment period and a direct comparison, showed a 2.5 percentage-point gap in favour of tirzepatide. Neither result is wrong. They measure different things in different ways. But the direct trial is generally considered stronger evidence for a pairwise comparison.

Where the individual drugs stand

Tirzepatide

Approved by the FDA (as Mounjaro for type 2 diabetes, Zepbound for weight management) and the EMA (as Mounjaro for both indications). The SURMOUNT-1 Phase 3 trial reported 20.9% mean weight loss at 72 weeks on the 15 mg dose^[3]. Tirzepatide is a dual GIP/GLP-1 receptor agonist.

Semaglutide

Approved as Wegovy (2.4 mg, weight management) and Ozempic (type 2 diabetes) by both the FDA and the EMA. The STEP 1 trial reported 14.9% mean weight loss at 68 weeks on 2.4 mg^[4]. Semaglutide is a GLP-1 receptor agonist.

CagriSema

Not yet approved. Novo Nordisk filed a New Drug Application with the FDA in December 2025^[5]. CagriSema combines cagrilintide (a long-acting amylin analogue) with semaglutide (a GLP-1 receptor agonist) in a single weekly injection. The REDEFINE 1 trial reported 20.4% mean weight loss at 68 weeks versus 14.9% for semaglutide alone and 3.0% for placebo^[6].

Cagrilintide

Not approved as a standalone treatment. A Phase 2 dose-finding trial published in The Lancet showed dose-dependent weight loss up to about 10.8% at 26 weeks^[7]. Cagrilintide works through amylin receptors in the brainstem to reduce appetite. Its main clinical role at this point is as the amylin component of CagriSema.

What this means for readers

This meta-analysis is useful as a map of the current field. It confirms that higher-dose tirzepatide and the CagriSema combination sit at the top of the efficacy ranking for weight loss, that semaglutide 2.4 mg is effective but produces less weight loss than either, and that cagrilintide alone is less effective than the combinations. None of that is surprising given the individual trial results, but having it laid out in a single analysis with consistent statistical methods is helpful.

The safety findings are reassuring in one sense: serious adverse events were not elevated versus placebo for any treatment. But gastrointestinal side effects remain the dominant burden across the class, and this meta-analysis does not capture rarer signals that might emerge with larger post-marketing datasets.

The limitation to keep in mind: for the CagriSema-versus-tirzepatide comparison specifically, the direct head-to-head data (REDEFINE 4) is more informative than the indirect NMA estimate. The NMA suggests near-equivalence; the direct trial showed a gap. Readers following this space should weigh the direct evidence more heavily for that particular matchup.

This article is for educational and journalistic purposes only and does not constitute medical advice. The treatments discussed are prescription medicines. Always consult a qualified healthcare professional before starting, changing, or stopping any treatment.